BIOLOGIAL RESPONSE MODIFIERS AS THERAPIES FOR AIDS

生物反应调节剂作为艾滋病疗法

• 批准号: 2296953
• 负责人: JULIE L. EISEMAN
• 金额: $ 26.57万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-01 至 1992-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2296953
• 关键词: BIOLOGIAL; RESPONSE; MODIFIERS; THERAPIES; AIDS

The objective of this contract is to facilitate the entry of biological response modifiers (BRMs) into clinical trials. This will be accomplished by examining the potential efficacy of BRMs in an appropriate retrovirus infected animal model. Efforts will be made to evaluate BRMs alone or in combination with other drugs in an appropriate animal/retrovirus model to determine their potential usefulness as a therapy for AIDS. BRMs are agents or methods used to alter the host's biological response to infection with a resultant therapeutic effect. BRMs may function in several ways. Some increase the host's antiviral responses by augmenting or restoring the effector arms directly or indirectly. Others may function to increase the growth and differentiation of lymphocytes or macrophages thus increasing the ability of the host to tolerate damage by cytotoxic drugs that may be used in the treatment of AIDS. Cytokines, lymphokines, monokines, growth factors, tumor necrosis factors and inducers of these proteins are examples of some of the BRMs known to date. The Division of Cancer Treatment (DCT) of the National Cancer Institute has ben developing these agents in the treatment of tumors. Until recently little work has been done to develop the use of BRMs alone or in combination with other drugs for the treatment of viral infections. It may be that therapies for AIDS which require long term treatment with an antiviral agent (e.g. nucleoside analogue) may require combination therapy with a modualtor of the immune response. BRMs could be used to decrease the toxicity of the drug by increasing the number of lymphocytes or aid in the immune response against this viral infection. At present, research into this area needs to be increased. It is the purpose of this solicitation to develop the use of BRMs for AIDS therapy. This will be accomplished by evaluation BRMs alone or in combination with other drugs in an retrovirusanimal model which mimics the disease AIDS.

本合同的目的是促进进入 生物反应调节剂（BRM）进入临床试验。 这将 通过检查 BRM 的潜在功效来完成 适当的逆转录病毒感染动物模型。 努力将会 用于单独或与其他药物联合评估 BRM 在适当的动物/逆转录病毒模型中确定它们的 作为艾滋病治疗的潜在用途。 BRM 是代理人或 用于改变宿主对感染的生物反应的方法 从而产生治疗效果。 BRM 可以发挥作用 有几种方法。 有些通过以下方式增强宿主的抗病毒反应 直接或间接增强或恢复效应器臂。 其他可能起到促进生长和分化的作用 从而增加淋巴细胞或巨噬细胞的能力 宿主能够耐受可能用于细胞毒性药物的损伤 艾滋病的治疗。 细胞因子、淋巴因子、单核因子、 生长因子、肿瘤坏死因子及其诱导剂 蛋白质是迄今为止已知的一些 BRM 的例子。 这 国家癌症中心癌症治疗科 (DCT) 研究所一直在开发这些药物来治疗 肿瘤。 直到最近，在开发 单独使用 BRM 或与其他药物联合使用 治疗病毒感染。 艾滋病的治疗方法可能是这样的 需要使用抗病毒药物进行长期治疗（例如 核苷类似物）可能需要联合治疗 免疫反应的调节剂。 BRM 可用于 通过增加药物的数量来降低药物的毒性 淋巴细胞或有助于针对这种病毒的免疫反应 感染。 目前，该领域的研究亟待 增加。 本次征集的目的是开发使用 用于艾滋病治疗的 BRM。 这将通过以下方式完成 单独评估 BRM 或与其他药物联合使用 模仿艾滋病疾病的逆转录病毒动物模型。